Treatment of hepatocellular carcinoma and liver metastases with hafnium oxide nanoparticles activated by SBRT: A phase I/II trial.

N. Jaksic,Marc Pracht,Yann Rolland,Thierry de Baere,Jerome Durand-Labrunie,Jean-Pierre Bronowicki,Véronique Vendrely,Antonio Sa Cunha,V. Croisé Laurent,Emmanuel Rio,Samuel Le Sourd,Patricia Saïd,Sebastian Freund,Edwina Baskin-Bey,P. Gustin,C. Perret,Didier Peiffert,Eric Deutsch,Enrique Chajon

Treatment of hepatocellular carcinoma and liver metastases with hafnium oxide nanoparticles activated by SBRT: A phase I/II trial.

2020

N. Jaksic
Marc Pracht
Yann Rolland
Thierry de Baere
Jerome Durand-Labrunie
Jean-Pierre Bronowicki
Véronique Vendrely
Antonio Sa Cunha
V. Croisé Laurent
Emmanuel Rio
Samuel Le Sourd
Patricia Saïd
Sebastian Freund
Edwina Baskin-Bey
P. Gustin
C. Perret
Didier Peiffert
Eric Deutsch
Enrique Chajon

537Background: Treatment of unresectable liver cancer or liver metastases (mets) by stereotactic body radiotherapy is well tolerated but limited by the need to preserve liver function. Increasing e...

Keywords:

Hepatocellular carcinoma
Hafnium oxide
Cancer research
Nanoparticle
Medicine
Pathology
Urology
Liver cancer
liver function
phase i ii
stereotactic body radiotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations